A Phase 2 interventional study of LT3001 Drug Product and Placebo in Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Lumosa Therapeutics Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.
Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 160th largest by enrollment of the 364 interventional ones that give a count, is one of 36 that started in 2022, is one of 71 in phase 2, and was the 335th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+
Magnetic Tides · Sites in United States
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Abrexa Pharmaceuticals, Inc. · Sites in United States
Ages 18–90
Medtronic Neurovascular Clinical Affairs · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
480 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 103 · Phase 3 46 · Phase 4 11
First in 1993; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 66 across the 364 interventional studies, 300 across the 111 observational. Of the 281 that completed or were terminated, 128 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 480 have an industry lead sponsor. The 10 most frequent:
Lumosa Therapeutics Co., Ltd. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Lumosa Therapeutics Co., Ltd. has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
48 of the studies in Ischemic Stroke with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07649135University of MinnesotaFeasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke | 2026-11-30 |
| NCT05085210Beth Israel Deaconess Medical CenterImproving Visual Field Deficits With Noninvasive Brain Stimulation | 2026-12 |
Add all 48 to your calendar (.ics) → With an account.
Among the 480 studies in Ischemic Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
This is a multicenter, double-blind, randomized, and placebo-controlled prospective Phase II clinical study, designed to evaluate LT3001 drug product versus placebo in subjects with AIS. The study is planned to take place in multiple countries. Subjects who participate in this trial should be treated with standard of care of AIS therapies when appropriate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Neuroimaging Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered by intravenous infusion
Drug: LT3001 Drug Product
Administered by intravenous infusion
Drug: Placebo
Administered by intravenous infusion
Administered by intravenous infusion
The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration.
There were no subjects in either treatment group who met the predefined criteria for the primary safety endpoint: the proportion of subjects with TEAEs judged to be probably or definitely related to the IP within 90 days after the first IP administration.
Time frame: within 90 days after the first IP administration
| Milestone | LT3001 Drug Product | Placebo |
|---|---|---|
| Started | 43 | 45 |
| Completed | 37 | 42 |
| Not completed | 6 | 3 |
There were no subjects in either treatment group who met the predefined criteria for the primary safety endpoint: the proportion of subjects with TEAEs judged to be probably or definitely related to the IP within 90 days after the first IP administration.
| Participants | LT3001 Drug Product | Placebo |
|---|---|---|
| The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration. | 0 | 0 |
Collected over From the time the subject received the first IP until the last follow-up visit, approximately 92 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LT3001 Drug Product | 4/43 (9.3%) | 12/43 (27.9%) | 37/43 (86%) |
| Placebo | 1/44 (2.3%) | 5/44 (11.4%) | 33/44 (75%) |
| Event | LT3001 Drug Product | Placebo |
|---|---|---|
| Stroke, Brain oedema, Encephalopathy, Neurological decompensationNervous system disorders | 6/43 | 4/44 |
| Colitis ischaemic, Inguinal herniaGastrointestinal disorders | 2/43 | 0/44 |
| Pneumonia, Pneumonia aspirationInfections and infestations | 2/43 | 0/44 |
| Fall, Traumatic subarachnoid haemorrhageInjury, poisoning and procedural complications | 2/43 | 0/44 |
| Leukopenia, NeutropeniaBlood and lymphatic system disorders | 1/43 | 0/44 |
| Cardio-respiratory arrestCardiac disorders | 0/43 | 1/44 |
| Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 1/44 |
| Event | LT3001 Drug Product | Placebo |
|---|---|---|
| UTI, Pneumonia, Pneumonia aspiration, COVID-19, ConjunctivitisInfections and infestations | 18/43 | 11/44 |
| Constipation, DiarrhoeaGastrointestinal disorders | 17/43 | 17/44 |
| Hyperlipidaemia, HypokalaemiaMetabolism and nutrition disorders | 16/43 | 12/44 |
| Headache, Stroke, Brain oedemaNervous system disorders | 13/43 | 9/44 |
| InsomniaPsychiatric disorders | 9/43 | 10/44 |
| Arthralgia, Muscle spasmsMusculoskeletal and connective tissue disorders | 9/43 | 7/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/43 | 7/44 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 7/43 | 3/44 |
| PyrexiaGeneral disorders | 6/43 | 4/44 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 6/43 | 3/44 |
ITT
| Age, Categorical(Participants) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 19 | 38 |
| >=65 years | 24 | 26 | 50 |
| Age, Continuous(years) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| Mean | 67.3 ± 12.28 | 65.7 ± 11.38 | 66.5 ± 11.79 |
| Sex: Female, Male(Participants) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| Female | 14 | 13 | 27 |
| Male | 29 | 32 | 61 |
| Race (NIH/OMB)(Participants) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 22 | 20 | 42 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 18 | 23 | 41 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Weight(Kg) | LT3001 Drug Product | Placebo | Total |
|---|---|---|---|
| Mean | 74.75 ± 16.723 | 74.28 ± 17.827 | 74.51 ± 17.198 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in May 2025, 33 months.
Results were first posted in Dec 2025, 7 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 33 months is above that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LT3001
Lumosa Therapeutics Co., Ltd.